Atea Pharmaceuticals, Inc. Common Stock
AVIR US04683R1068
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -78% | -48% | -37% | 4% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Berger Franklin M |
3.36 USD |
10,000 Sold |
33,614 USD |
15/01/2025 | 16/01/2025 |
| Berger Franklin M |
3.19 USD |
15,000 Sold |
47,885 USD |
15/01/2025 | 15/01/2025 |
| Berger Franklin M |
2.85 USD |
359,606 Sold |
1,023,475 USD |
10/12/2024 | 10/12/2024 |
| Sommadossi Jean-pierre CEO |
4.00 USD |
1,841 Sold |
7,368 USD |
17/09/2024 | 19/09/2024 |
| Sommadossi Jean-pierre CEO |
4.03 USD |
22,187 Sold |
89,469 USD |
17/09/2024 | 18/09/2024 |
| Sommadossi Jean-pierre CEO |
4.05 USD |
33,941 Sold |
137,319 USD |
17/09/2024 | 17/09/2024 |
| Polsky Bruce |
3.49 USD |
17,544 Sold |
61,144 USD |
20/06/2024 | 20/06/2024 |
| Sommadossi Jean-pierre CEO |
4.00 USD |
1,006 Sold |
4,024 USD |
05/06/2024 | 05/06/2024 |
| Horga Maria Arantxa CMO |
3.84 USD |
15,870 Sold |
60,963 USD |
31/01/2024 | 01/02/2024 |
| Foster Wayne CCO |
3.84 USD |
12,477 Sold |
47,904 USD |
31/01/2024 | 01/02/2024 |